Trial Profile

A Phase 2 Open-Label Study of Ozuriftamab Vedotin (BA3021) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ozuriftamab vedotin (Primary) ; Programmed cell death 1 receptor antagonists
Indications Head and neck cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Sponsors BioAtla

23 Oct 2025 According to a BioAtla media release, data from this study is being presented in a poster presentation at the International Papillomavirus Society (IPVS) Conference, taking place October 23-26, 2025, in Bangkok, Thailand.
26 Sep 2025 Status changed from recruiting to completed.
02 Jun 2025 According to a BioAtla media release, poster will be presenting today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting at the McCormick Place Convention Center in Chicago, Illinois.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com